CRISPR Therapeutics (CRSP) reported earnings of $1.43 per share in the first quarter of 2024, surpassing the Zacks Consensus Estimate of a loss of$1.63. In the year-ago period, the company had incurred a loss of 67 cents per share. The company’s total revenues, generated entirely from grant revenues, were $0.5 million in the first quarter. The reported figures significantly missed the Zacks Consensus Estimate of$8.3 million. In the year-ago quarter, the company generated revenues worth $100 million, which ...